FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 247 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on... December 9, 2020 One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... December 9, 2025 Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find... November 15, 2021 Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... December 12, 2025 Load more HOT NEWS 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... Veteran and His Loyal Dog Pass Away Within Hours Of Each... Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III...
